Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation

[1]  Lijuan Peng,et al.  Arg972 insulin receptor substrate‐1 polymorphism and risk and severity of rheumatoid arthritis , 2016, International journal of rheumatic diseases.

[2]  A. MacKenzie,et al.  The noncoding human genome and the future of personalised medicine , 2015, Expert Reviews in Molecular Medicine.

[3]  G. Rutter,et al.  Selective disruption of Tcf7l2 in the pancreatic β cell impairs secretory function and lowers β cell mass , 2014, Human molecular genetics.

[4]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2014, Diabetes Care.

[5]  D. Altshuler,et al.  Pathways Targeted by Antidiabetes Drugs Are Enriched for Multiple Genes Associated With Type 2 Diabetes Risk , 2014, Diabetes.

[6]  C. Currie,et al.  Mortality risk with sulphonylureas compared to metformin , 2014, Diabetes, obesity & metabolism.

[7]  J. Rey,et al.  Association of the rs7903146 and rs12255372 polymorphisms in the TCF7L2 gene with type 2 diabetes in a population from northeastern Brazil. , 2014, Genetics and molecular research : GMR.

[8]  Kapaettu Satyamoorthy,et al.  Population Specific Impact of Genetic Variants in KCNJ11 Gene to Type 2 Diabetes: A Case-Control and Meta-Analysis Study , 2014, PloS one.

[9]  L. Chuang,et al.  Genetic Variations in the Kir6.2 Subunit (KCNJ11) of Pancreatic ATP-Sensitive Potassium Channel Gene Are Associated with Insulin Response to Glucose Loading and Early Onset of Type 2 Diabetes in Childhood and Adolescence in Taiwan , 2014, International journal of endocrinology.

[10]  Aycan Aşık,et al.  IRS1 gene polymorphisms Gly972Arg and Ala513Pro are not associated with insulin resistance and type 2 diabetes risk in non-obese Turkish population , 2014, Meta gene.

[11]  Polin Haghverdizadeh,et al.  ABCC8 genetic variants and risk of diabetes mellitus. , 2014, Gene.

[12]  M. Broggini,et al.  Genetic markers for prediction of treatment outcomes in ovarian cancer , 2014, The Pharmacogenomics Journal.

[13]  L. Groop,et al.  TCF7L2 is a master regulator of insulin production and processing , 2014, bioRxiv.

[14]  G. Umpierrez,et al.  Sulfonylureas: A New Look at Old Therapy , 2014, Current Diabetes Reports.

[15]  J. Shaw,et al.  Global estimates of diabetes prevalence for 2013 and projections for 2035. , 2014, Diabetes Research and Clinical Practice.

[16]  A. Janež,et al.  CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients , 2014, European Journal of Clinical Pharmacology.

[17]  Hechao Li,et al.  Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China , 2014, Diabetologia.

[18]  F. Ashcroft,et al.  Molecular Mechanism of Sulphonylurea Block of KATP Channels Carrying Mutations That Impair ATP Inhibition and Cause Neonatal Diabetes , 2013, Diabetes.

[19]  T. Sanke,et al.  Kir6.2 E23K polymorphism is related to secondary failure of sulfonylureas in non‐obese patients with type 2 diabetes , 2013, Journal of diabetes investigation.

[20]  D. Hu,et al.  Association of rs12255372 in the TCF7L2 gene with type 2 diabetes mellitus: a meta-analysis , 2013, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[21]  R. Salam,et al.  Effect of CYP2C9 gene polymorphisms on response to treatment with sulfonylureas in a cohort of Egyptian type 2 diabetes mellitus patients , 2014, Comparative Clinical Pathology.

[22]  D. Hu,et al.  Meta-analysis of associations between TCF7L2 polymorphisms and risk of type 2 diabetes mellitus in the Chinese population , 2013, BMC Medical Genetics.

[23]  Jun Liu,et al.  Meta-analysis of the effect of KCNQ1 gene polymorphism on the risk of type 2 diabetes , 2012, Molecular Biology Reports.

[24]  Yan-yan Li.  The KCNJ11 E23K gene polymorphism and type 2 diabetes mellitus in the Chinese Han population: a meta-analysis of 6,109 subjects , 2012, Molecular Biology Reports.

[25]  N. Skolnik,et al.  Management of Hyperglycemia in Type 2 Diabetes , 2012 .

[26]  W. Z. Wan Ngah,et al.  Optimisation of glycaemic control during episodes of severe/acute hyperglycaemia in patients with type 2 diabetes mellitus , 2012, International Journal of Clinical Pharmacy.

[27]  I. Tkáč,et al.  KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. , 2012, European journal of internal medicine.

[28]  F. Ashcroft,et al.  Diabetes Mellitus and the β Cell: The Last Ten Years , 2012, Cell.

[29]  I. Tkáč,et al.  Variation in CDKAL1 gene is associated with therapeutic response to sulphonylureas. , 2012, Physiological research.

[30]  J. Florez,et al.  Pharmacogenetics in type 2 diabetes: potential implications for clinical practice , 2011, Genome Medicine.

[31]  A. El-sisi,et al.  Effect of genetic polymorphisms on the development of secondary failure to sulfonylurea in Egyptian patients with type 2 diabetes , 2011, Therapeutic advances in endocrinology and metabolism.

[32]  I. Tkáč,et al.  Variation in KCNQ1 is associated with therapeutic response to sulphonylureas , 2011, Medical science monitor : international medical journal of experimental and clinical research.

[33]  V. Nosikov,et al.  The carriage of risk variants of CDKAL1 impairs beta-cell function in both diabetic and non-diabetic patients and reduces response to non-sulfonylurea and sulfonylurea agonists of the pancreatic KATP channel , 2011, Acta Diabetologica.

[34]  C. Adithan,et al.  Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients , 2011, European Journal of Clinical Pharmacology.

[35]  I. Tkáč,et al.  Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes , 2011, Diabetes, obesity & metabolism.

[36]  M. Stumvoll,et al.  TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes , 2011, BMC Medical Genetics.

[37]  I. Roots,et al.  Genetic variants of the insulin receptor substrate‐1 are influencing the therapeutic efficacy of oral antidiabetics , 2010, Diabetes, obesity & metabolism.

[38]  C. Aquilante.  Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms , 2010, Expert review of cardiovascular therapy.

[39]  A. Hattersley,et al.  Loss‐of‐Function CYP2C9 Variants Improve Therapeutic Response to Sulfonylureas in Type 2 Diabetes: A Go‐DARTS Study , 2010, Clinical pharmacology and therapeutics.

[40]  A. Šimundić,et al.  Metabolic control in type 2 diabetes is associated with sulfonylurea receptor-1 (SUR-1) but not with KCNJ11 polymorphisms. , 2009, Archives of medical research.

[41]  A. McLachlan,et al.  Influence of genetic polymorphisms on the pharmacokinetics and pharmaco-dynamics of sulfonylurea drugs. , 2009, Current drug metabolism.

[42]  E. Pearson,et al.  Translating TCF7L2: from gene to function , 2009, Diabetologia.

[43]  Anna L. Gloyn,et al.  Type 2 Diabetes Susceptibility Gene TCF7L2 and Its Role in β-Cell Function , 2009, Diabetes.

[44]  Peter Almgren,et al.  Clinical risk factors, DNA variants, and the development of type 2 diabetes. , 2008, The New England journal of medicine.

[45]  Xiping Xu,et al.  Ser1369Ala Variant in Sulfonylurea Receptor Gene ABCC8 Is Associated With Antidiabetic Efficacy of Gliclazide in Chinese Type 2 Diabetic Patients , 2008, Diabetes Care.

[46]  A. Hofman,et al.  Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea , 2008, Pharmacogenetics and genomics.

[47]  A. Hofman,et al.  Cytochrome P450 2C9 *2 and *3 Polymorphisms and the Dose and Effect of Sulfonylurea in Type II Diabetes Mellitus , 2008, Clinical pharmacology and therapeutics.

[48]  S. Ellard,et al.  Mutations in the ABCC8 gene encoding the SUR1 subunit of the KATP channel cause transient neonatal diabetes, permanent neonatal diabetes or permanent diabetes diagnosed outside the neonatal period , 2007, Diabetes, obesity & metabolism.

[49]  M. Weedon,et al.  The importance of TCF7L2 , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[50]  H. Heien,et al.  Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen. , 2007, The American journal of managed care.

[51]  M. McCarthy,et al.  Variation in TCF7L2 Influences Therapeutic Response to Sulfonylureas , 2007, Diabetes.

[52]  H. Kuang,et al.  Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes. , 2007, Diabetes research and clinical practice.

[53]  W. Cefalu.  Pharmacotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus: Rationale and Specific Agents , 2007, Clinical pharmacology and therapeutics.

[54]  J. Youngren.  Regulation of insulin receptor function , 2007, Cellular and Molecular Life Sciences.

[55]  David M Nathan,et al.  TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. , 2006, The New England journal of medicine.

[56]  Agostino Gnasso,et al.  The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. , 2006, The Journal of clinical endocrinology and metabolism.

[57]  N. Clark,et al.  Standards of Medical Care in Diabetes: Response to Power , 2006 .

[58]  T. Hansen,et al.  IRS1, KCNJ11, PPARγ2 and HNF‐1α: do amino acid polymorphisms in these candidate genes support a shared aetiology between type 1 and type 2 diabetes? , 2006, Diabetes, obesity & metabolism.

[59]  I. Tsuji,et al.  Secondary sulfonylurea failure: comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide. , 2005, Diabetes research and clinical practice.

[60]  J. Brockmöller,et al.  Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. , 2005, British journal of clinical pharmacology.

[61]  C. Kahn,et al.  Human Insulin Receptor Substrate-1 (IRS-1) Polymorphism G972R Causes IRS-1 to Associate with the Insulin Receptor and Inhibit Receptor Autophosphorylation* , 2005, Journal of Biological Chemistry.

[62]  A. Gnasso,et al.  The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. , 2004, Diabetes care.

[63]  F. Ashcroft,et al.  Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. , 2004, The New England journal of medicine.

[64]  Aesha Drozdowski,et al.  Standards of medical care in diabetes. , 2004, Diabetes care.

[65]  E. Feskens,et al.  Gly972Arg variant in the insulin receptor substrate-1 gene and association with Type 2 diabetes: a meta-analysis of 27 studies , 2003, Diabetologia.

[66]  R. DeFronzo.  Pharmacologic Therapy for Type 2 Diabetes Mellitus , 1999, Annals of Internal Medicine.

[67]  R. Holman,et al.  UKPDS 26: sulphonylurea failure in non‐insulin‐dependent diabetic patients over six years , 1998, Diabetic medicine : a journal of the British Diabetic Association.